Investigational Therapeutics That Restore Brain Synapses
Spinogenix is pioneering first-in-class, investigational therapeutics that restore brain synapses to improve the lives of patients worldwide.
A New Approach to the Brain’s Lost Connections
Spinogenix has designed small molecules to help restore the brain connections (synapses) in neurodegenerative, neuropsychiatric and neurodevelopmental conditions including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, schizophrenia, Fragile X Syndrome (FXS) and many others.
Latest Press Releases
Spinogenix Announces Phase 2b Trial for Autism Using Novel Brain-Wave Screening to Target Treatment
October 14, 2026
The Trial, a First-of-Its-Kind Prospective Use of a Brain-Activity Inclusion Criterion in Neurodevelopmental Drug Development, Will Enroll Patients Exhibiting Elevated Gamma Band EEG Power
Spinogenix Announces World Health Organization Approval of “Codabakalner” as International Nonproprietary Name for SPG601
July 16, 2026
Spinogenix, Inc. announced today that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization has approved "codabakalner" as the non-proprietary name for the Company's investigational therapy, SPG601.
Spinogenix Reports Positive Data on Alzheimer’s Patients Who Continued Treatment With Tazbentetol For Up To 84 Weeks
July 14, 2026
Tazbentetol, a First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Demonstrated Favorable Safety Profile and Durable Therapeutic Benefits
In the News
Spinogenix’s Alzheimer’s drug touts disease-modifying potential in Phase IIa study
December 9, 2025
Topline data from a completed phase 2a trial (NCT05882695) highlighted the therapeutic benefits of SPG302, a synaptic regenerative drug, to treat patients with amyotrophic lateral sclerosis (ALS). All told, treatment...
From the Blog
Rethinking Alzheimer’s Treatment: It’s Time for a New Playbook in the Fight for Memory
December 1, 2025
Authored by Stella Sarraf, PhD CEO, Founder In September, we recognized World Alzheimer’s Month and championed the much-needed attention and awareness to one of the greatest health crises of our...